NCT06755684View on ClinicalTrials.gov

Neoadjuvant Befotertinib Combined Bevacizumab or Platinum-based Double Chemotherapy for Resectable Locally-advanced EGFR Mutation-positive Non-Small Cell Lung Cancer

PHASE2RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

November 7, 2024

Primary Completion Date

December 31, 2025

Study Completion Date

December 31, 2028

Conditions

EGFRNon-Small Cell Lung CancerLocally Advanced Non-Small Cell Lung CancerPemetrexedCarboplatinBevacizumabAntineoplastic AgentsTyrosine Kinase Inhibitor

Interventions

DRUG

Befotertinib combined Bevacizumab

DRUG

Befotertinib combined platinum-based double chemotherapy

Trial Locations (1)

200433

RECRUITING

Shanghai Pulmonary Hospital, Shanghai

All Listed Sponsors

lead

Peng Zhang

OTHER